| Metric | Details |
|---|---|
| Entity / Legal Name | Capital Vision Services LLC (d/b/a MyEyeDr.) |
| Sponsor / Owner | Goldman Sachs Asset Management & Charlesbank Capital Partners |
| S&P / Moody‑s Rating | NR / B3 |
| Rating Outlook | Stable (Moody‑s) |
| Investment Grade Status | Non‑Investment Grade — Highly Speculative |
| Sector | Healthcare / Vision Care & Optical Retail |
| Headquarters | Vienna, Virginia |
| US Location Count | 869+ locations (including Rx Optical brand) in 27 states |
| Cap Rate Range | 7.00% – 8.50% |
| Typical Lease Term | 10 – 15 years (NNN) |
| Guarantee Type | Corporate (Capital Vision Services LLC) |
| Typical Building Size | 1,800 – 3,500 SF |
| Typical Price Range | $800,000 – $3,500,000 |
MyEyeDr Business Overview & NNN Investment Profile
MyEyeDr. is one of the largest and fastest-growing vision care providers in the United States, operating 869 locations (including 48 under the Rx Optical brand) across 27 states as of the end of 2024. The company was founded more than 20 years ago in the Washington, D.C. metro area, where it grew from fewer than 60 locations into the dominant regional vision care provider before expanding nationally. In 2019, Goldman Sachs Asset Management acquired the parent company, Capital Vision Services, alongside Charlesbank Capital Partners and management. Since the Goldman acquisition, MyEyeDr. has roughly doubled its footprint through an aggressive combination of practice acquisitions and, more recently, de novo location development.
MyEyeDr.’s business model mirrors the DSO (dental support organization) framework applied to optometry: the company acquires independent optometry practices and provides business management, marketing, human resources, claims processing, and accounting support while the doctors maintain clinical autonomy. This “supported autonomy” model has proven highly effective at consolidating the fragmented optometry market. The company plans to open 20 de novo locations in 2025 and approximately 50 per year thereafter, targeting suburban retail centers, lifestyle centers, and freestanding locations of 1,800 to 3,000 square feet with strong visibility and co-tenancy alongside grocers and national fast-casual brands.
MyEyeDr. carries a Moody‑s B3 rating, placing it in the highly speculative tier below investment grade. The rating reflects the company’s leveraged capital structure typical of private equity-backed healthcare rollups. However, the Goldman Sachs sponsorship provides access to capital and operational expertise that smaller PE-backed healthcare platforms lack. Goldman Sachs Merchant Banking has invested approximately $180 billion across corporate, real estate, and infrastructure strategies since 1986, and healthcare is a core focus area. NNN investors benefit from the implicit financial support of one of the world’s most prominent financial institutions, though the formal guarantee on each lease flows through the Capital Vision Services entity, not Goldman Sachs directly.
Why MyEyeDr Matters for NNN Investors
Vision care is one of the most recession-resistant and e-commerce-resistant segments of healthcare. Eye exams, prescription eyeglasses, contact lenses, and medical eye care cannot be delivered online, and the need for vision correction increases with age in a population that is steadily getting older. MyEyeDr. locations are small-format retail properties that landlords love: they generate steady foot traffic, require no special ventilation or hazardous materials handling, operate during standard retail hours, and appeal to a broad demographic. The brand’s flexibility on real estate, from inline spaces to outparcels to converted freestanding buildings, means MyEyeDr. NNN properties exist across a wide range of suburban retail formats.
The properties are also highly re-tenantable. A 2,000 to 3,000 square foot optical shop in a suburban retail center can be converted to virtually any personal services, medical, or small retail use with minimal capital investment. This real estate quality provides meaningful downside protection even at the B3 credit level.
Cap Rate Analysis & Pricing for MyEyeDr NNN Properties
MyEyeDr. NNN properties trade in the 7.00% to 8.50% cap rate range as of Q1 2026. The small format sizes keep total investment amounts modest, typically $800,000 to $3.5 million, making these accessible to individual investors. Per-square-foot rents generally range from $30 to $55 NNN depending on the market and co-tenancy. Properties in high-traffic suburban centers with strong national co-tenants and long remaining terms trade at the tighter end of the range.
| Comparable Healthcare NNN Tenant | S&P / Moody‑s | Cap Rate Range |
|---|---|---|
| EyeCare Partners | NR / Caa2 | 7.50% – 9.50% |
| Aspen Dental | NR / B3 | 6.50% – 8.00% |
| Pacific Dental Services | B / B2 | 7.00% – 8.50% |
No. MyEyeDr. (Capital Vision Services) carries a Moody‑s B3 rating, placing it in the highly speculative non-investment grade tier. The company is backed by Goldman Sachs Asset Management, which provides significant financial sponsorship, but the formal credit obligation sits at the Capital Vision Services entity level, not Goldman Sachs.
MyEyeDr. NNN properties trade in the 7.00% to 8.50% cap rate range as of Q1 2026, reflecting the B3 credit profile and small-format suburban retail locations.
The Only MyEyeDr NNN Advisor Whose Fee Comes From the Deal, Not From You
In NNN buyer representation, the listing broker typically pays a cooperating commission to the buyer’s broker. On the majority of transactions, this means there is no separate fee to you as the buyer. Where a cooperating commission is not available, our compensation is agreed upon with you in advance so there are never surprises.
Find It — MyEyeDr vision care locations sourced with Capital Vision Services guarantee confirmation, Goldman Sachs sponsorship analysis, and suburban retail location quality assessment before you commit.
Fund It — B3-rated optical NNN backed by Goldman Sachs PE requires lenders who understand sponsor-backed healthcare. We have 150+ lender relationships to find competitive terms.
Exit It — Selling a MyEyeDr property? Vision care NNN in prime suburban retail locations attracts consistent buyer demand. We help maximize your exit price.
Get Your Free MyEyeDr NNN Consultation →
In a 1031 exchange? Tell us your timeline — we move faster.
Related NNN Tenants
- Ascension
- Aspen Dental
- Athletico
- BioLife Plasma
- Concentra / Humana
- Corewell Health
- CSL Plasma
- DaVita Dialysis
- EyeCare Partners
- Fresenius
- Grifols
- Henry Ford Health
- HCA Healthcare
- Heartland Dental
- Mary Washington Healthcare
- McLaren Health Care
- Oak Street Health
- Piedmont Healthcare
- Sparrow Health
- Trinity Health
- U of M Health
- University of Pittsburgh Medical Center (UPMC)
- Acadia Healthcare
- AFC Urgent Care
- ATI Physical Therapy
- CityMD / Summit Health
- Encompass Health
- Fast Pace Urgent Care
- MedExpress Urgent Care
- NextCare Urgent Care
- Octapharma Plasma
- Pacific Dental Services
- Select Physical Therapy
- Smile Brands
- VCA Animal Hospitals
- WellNow Urgent Care
- Banfield Pet Hospital
- Labcorp
- National Vision
- Quest Diagnostics
Own a MyEyeDr Property? Capital Markets Strategies Beyond Selling
Maturing debt and considering refinancing? Our capital markets team maintains 150+ lender relationships underwriting NNN properties across investment-grade and non-investment-grade credit tiers. We structure rate-and-term refinancing, cash-out refis, and bridge-to-perm takeouts.
Evaluating a 1031 exchange or disposition? We represent both sides of MyEyeDr NNN transactions — whether you are looking to exit at peak value, exchange into a higher-quality credit tenant, or reposition within the same sector.
Need a current valuation? We maintain live comps on MyEyeDr NNN transactions and can produce a Broker Opinion of Value within 48 hours reflecting today’s cap rate market.
Own multiple MyEyeDr properties? Considering an off-market sale?
Investment Grade represents owners on confidential disposition of MyEyeDr portfolios and individual properties through off-market direct-to-principal distribution to specialty REITs, private equity funds, and family offices. MyEyeDr buyer demand runs deep, and portfolio sales consistently produce stronger pricing than sequential individual sales because the institutional buyer pool is structured around portfolio acquisition.
For multi-property owners considering a portfolio disposition, see Selling Investment Grade NNN Off-Market: Tenant-by-Tenant Buyer Demand. For the full off-market framework covering individual property dispositions, sale-leasebacks, and 1031 coordination, see Off-Market CRE Sales: The Complete 2026 Guide.
The pre-listing conversation is at no cost and fully confidential. Email team@investmentgrade.com or see contact Investment Grade.


